Patients with rheumatoid arthritis (RA) who don't do well with the available biologic therapies may soon have another therapeutic option: monoclonal antibodies that target granulocyte-macrophage colony-stimulating factor (GM-CSF). MedPage Today, 02/20/2014. (Also see: Rheumatoid Arthritis Treatments)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.